Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO® (vorasidenib), will be presented in a rapid oral session on May 31 at 4:36 p.m. CDT Results show median progression-free survival among patients...
Hence then, the article about servier to present extended follow up results from the phase 3 indigo trial showing durable and sustained treatment benefits of voranigo vorasidenib at asco 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026 )
Also on site :
- I Thought I’d Met a Great Guy. When He Refused to Treat His Genital Infection, I Did Something I Never Wanted to Do.
- Beloved Singer-Songwriter, Compared to Carole King and Joni Mitchell, Was ‘All But Forgotten’ Until 26 Years After Her Death
- In ‘Magazine’, Director Alexandra Pechman Brings a Bygone Era of Print Media (and the 2010s) to TIFF Audiences